Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 5
1983 6
1984 4
1985 11
1986 14
1987 11
1988 11
1989 4
1990 2
1991 4
1992 1
1993 2
1994 1
1995 1
1996 2
1997 3
1998 2
1999 5
2000 1
2001 6
2002 5
2003 6
2004 7
2005 3
2006 3
2007 3
2008 8
2009 8
2010 8
2011 4
2012 4
2013 13
2014 9
2015 11
2016 11
2017 12
2018 9
2019 4
2020 4
2021 4
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Results by year

Filters applied: . Clear all
Page 1
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. Cameron D, et al. Among authors: leyland jones b. Lancet. 2017 Mar 25;389(10075):1195-1205. doi: 10.1016/S0140-6736(16)32616-2. Epub 2017 Feb 17. Lancet. 2017. PMID: 28215665 Free PMC article. Clinical Trial.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Piccart-Gebhart MJ, et al. Among authors: leyland jones b. N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306. N Engl J Med. 2005. PMID: 16236737 Free article. Clinical Trial.
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R. Sicklick JK, et al. Among authors: leyland jones b. Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22. Nat Med. 2019. PMID: 31011206 Free PMC article. Clinical Trial.
Whither HER2-related therapeutics?
De P, Leyland-Jones B. De P, et al. Among authors: leyland jones b. J Clin Oncol. 2010 Mar 1;28(7):1091-6. doi: 10.1200/JCO.2009.25.8624. Epub 2010 Feb 1. J Clin Oncol. 2010. PMID: 20124168 No abstract available.
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Symmans WF, et al. Among authors: leyland jones b. JAMA Oncol. 2021 Nov 1;7(11):1654-1663. doi: 10.1001/jamaoncol.2021.3690. JAMA Oncol. 2021. PMID: 34529000 Free PMC article. Clinical Trial.
Dose scheduling--Herceptin.
Leyland-Jones B. Leyland-Jones B. Oncology. 2001;61 Suppl 2:31-6. doi: 10.1159/000055399. Oncology. 2001. PMID: 11694785 Review.
5-Methyltetrahydrohomofolate.
O'Dwyer PJ, Wagner BH, Hoth DF, Leyland-Jones B. O'Dwyer PJ, et al. Among authors: leyland jones b. Invest New Drugs. 1987;5(3):215-8. doi: 10.1007/BF00175290. Invest New Drugs. 1987. PMID: 3312079 Review.
Response.
Rae JM, Leyland-Jones B, Regan M. Rae JM, et al. Among authors: leyland jones b. J Natl Cancer Inst. 2014 Apr 3;106(5):dju064. doi: 10.1093/jnci/dju064. J Natl Cancer Inst. 2014. PMID: 24700799 No abstract available.
Pyrazole: preclinical reassessment.
O'Dwyer PJ, King SA, Plowman J, Grieshaber CK, Hoth DF, Leyland-Jones B. O'Dwyer PJ, et al. Among authors: leyland jones b. Invest New Drugs. 1988 Dec;6(4):305-10. doi: 10.1007/BF00173649. Invest New Drugs. 1988. PMID: 3068185 Review.
229 results